Company intelligence / Profile preview

Libra Pharmaceutical

San Diego, California, United Stateslibrapharma.pk ↗

Ownership: Private
Development stage: Commercial

Overview

Libra Therapeutics is developing novel small molecule therapeutics that enhance lysosome function and increase autophagy to treat neurodegenerative diseases. Their lead TRPML1 program is in pre-clinical development with IND-enabling studies projected to start in the first half of 2024 and Phase 1 studies on track for 2025[6][8].

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Partnerships

Confidential discussions with potential clinical development partners for TRPML1 program[6]

Beyond the preview

Go deeper on Libra Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Libra Pharmaceutical.

Explore the full profile